Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Austin, TX, USA, June 10, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Neoantigen Cancer Vaccine Market Size, Trends and Insights By Product...
-
- Deep and durable responses in drug-resistant KRAS-G12C- and EGFR-mutant NSCLC - Best-in-class safety profile highlights potential for development in combination to treat patients with...
-
Announced accepted oral presentation of positive phase 3 randomized placebo controlled clinical trial results of CAN-2409 (aglatimagene besadenovec) in localized prostate cancer at the 2025 American...
-
Recently announced positive data from pivotal randomized, placebo-controlled phase 3 clinical trial of CAN-2409 in intermediate-to-high risk, localized prostate cancerRecently announced positive final...
-
New York, USA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Non-Small Cell Lung Cancer Market Set for Significant Growth Across the 7MM During the Study Period (2025-2034) Due to the Rising Novel Therapeutic...
-
Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma Interest Providence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ: OCEA) today announced newly...
-
Immuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)
-
Immuneering to Present at the Piper Sandler 36th Annual Healthcare Conference
-
– VIRO-25 trial to assess efficacy & safety of olvimulogene nanivacirepvec (Olvi-Vec) & platinum-doublet + physician's choice of immune checkpoint inhibitor compared to docetaxel in recurrent...
-
Immuneering to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference